US2016031975A1PendingUtilityA1

Compositions and Methods for Antibodies Targeting Complement Protein C5

52
Assignee: DIEFENBACH-STREIBER BEATEPriority: Aug 5, 2008Filed: Apr 28, 2015Published: Feb 4, 2016
Est. expiryAug 5, 2028(~2.1 yrs left)· nominal 20-yr term from priority
A61P 7/00C07K 2317/92C07K 2317/24C07K 2317/622C07K 16/18C07K 2317/76C07K 2317/55C07K 2317/21C07K 2317/565C07K 2317/14A61K 39/395
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . An isolated antibody, or an antigen binding fragment thereof, comprising a heavy chain variable region having the sequence of SEQ ID NO: 7 and a light chain variable region having the sequence of SEQ ID NO: 8. 
     
     
         18 . The antibody, or an antigen binding fragment thereof, of  claim 17 , wherein said antibody is a monoclonal antibody. 
     
     
         19 . The antibody, or an antigen binding fragment thereof, of  claim 18 , wherein said antibody is a human or humanized antibody. 
     
     
         20 . The antibody, or an antigen binding fragment thereof, of  claim 18 , wherein said antibody is a chimeric antibody. 
     
     
         21 . The antibody, or an antigen binding fragment thereof, of  claim 18 , wherein said antibody comprises a human heavy chain constant region and a human light chain constant region. 
     
     
         22 . The antibody, or an antigen binding fragment thereof, of  claim 18 , wherein said antibody is a single chain antibody. 
     
     
         23 . The antibody, or an antigen binding fragment thereof, of  claim 18 , wherein said antibody is a Fab fragment. 
     
     
         24 . The antibody, or an antigen binding fragment thereof, of  claim 18 , wherein said antibody is a scFv. 
     
     
         25 . The antibody, or an antigen binding fragment thereof, of  claim 18  binds to both human complement C5 and cynomolgus complement C5. 
     
     
         26 . The antibody of  claim 18 , or an antigen binding fragment thereof, is an IgG isotype. 
     
     
         27 . The antibody, or an antigen binding fragment thereof, of  claim 17 , wherein said antibody comprises a heavy chain having the sequence of SEQ ID NO: 9 and a light chain having the sequence of SEQ ID NO: 10.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.